Supernus Pharmaceuticals (DE:S49)
NASDAQ:S49
S49 Stock Chart & Stats
€41.60
€0.80(2.26%)
At close: 4:00 PM EST
€41.60
€0.80(2.26%)
Day’s Range― - ―
52-Week Range€26.40 - €49.00
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€2.30B
Enterprise Value€2.54B
Total Cash (Recent Filing)€384.24M
Total Debt (Recent Filing)€40.90M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 11, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding58,039,722
10 Day Avg. Volume11
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.64
Price to Sales (P/S)3.90
P/FCF Ratio61.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.05Price Target Upside29.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.11
Revenue Forecast (FY)€734.79M
Bulls Say, Bears Say
Bulls Say
Acquisition SynergiesRealization of Sage acquisition synergies is improving operating performance and is reflected in management's forward operating earnings framework, indicating enhanced profitability and operating efficiency.
Product Commercialization MomentumZurzuvae's growing adoption among OBGYN prescribers and rising repeat writers, together with accelerating uptake of the postpartum depression product, validates the multi-product central nervous system strategy and broadens revenue streams.
Supply ResolutionResolution of Onapgo supply disruption enables resumption of new patient starts and conversion of the backlog of enrollment forms, supporting revenue growth as confirmed demand is fulfilled.
Bears Say
Backlog Conversion Execution RiskSuccessful recovery depends on converting the patient backlog and qualifying a secondary supplier, creating execution risk that could limit expected revenue if conversion or supply stability falters.
Guidance Sensitivity To Waitlist ConversionGuidance assumes conversion of patients already in active processing, making reported results sensitive to additional waitlist conversions and exposing the outlook to downside if demand converts more slowly than assumed.
Rebate-related Revenue PressureQelbree experienced a one-time rebating impact that increased discounts and reduced reported revenue, highlighting vulnerability of sales to reimbursement and pricing adjustments.
Supernus Pharmaceuticals News
S49 FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was €26.40 and its highest was €49.00 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is €2.30B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 62 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on May 05, 2026. The company reported €0.519 earnings per share for the quarter, beating the consensus estimate of €0.257 by €0.262.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.37.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 58,039,722 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of €0.519 in its last earnings report, beating expectations of €0.257. Following the earnings report the stock price went up 4.854%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:S49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€54.05 (29.94% Upside)
€54.05 (29.94% Upside)
Blogger Sentiment
Bullish
DE:S49 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.17%
12-Months-Change
Fundamentals
Return on Equity
-2.73%
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
S49 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple products with robust revenue growth (total revenue +39% YoY; growth products +56% YoY), improving non-GAAP profitability, a healthy cash position (~$384M) and an advancing R&D pipeline. Offsetting these positives are meaningful increases in operating expenses (combined R&D and SG&A up ~40.8% YoY), ongoing GAAP losses (albeit reduced), supply constraints and conversion challenges for Onepco, and timing / regulatory risk related to bringing a second supplier online. Management reiterated full-year guidance ranges and emphasized continued focus on corporate development and supply backups. Overall, the positive top-line growth, improved profitability metrics, strong product-specific trends and solid balance sheet outweigh the near-term expense and supply risks.View all DE:S49 earnings summariesS49 Stock 12 Month Forecast
Average Price Target
€54.05
▲(29.94% Upside)
Technical Analysis
Options Prices
Currently, No data available
---